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Abstract 
BACKGROUND: Autoimmune liver disease (AILD) encompasses three main distinct 
clinical diseases: autoimmune hepatitis, primary biliary cirrhosis and primary 
sclerosing cholangitis. These conditions are an important, yet under-appreciated 
cause of patient morbidity and mortality with ongoing unmet needs for further 
research and clinical advances. 
KEY MESSAGES: There is observational evidence for genetic predisposition, with all 
three conditions being more common in first degree relatives. AILD is associated 
with the presence of auto-antibodies and higher risks of other non-hepatic auto-
immune conditions. Genetic risk association studies have identified HLA and non-
HLA risk loci for the development of disease, with some HLA loci providing 
prognostic information. This re-enforces the concept that genetic predisposition to 
autoimmunity is important in the context of environment exposure.  Such 
environmental triggers are unclear but relevant risks include smoking, drug and 
xenobiotic exposure as well as the complexities of the microbiome. There is 
evidence for a loss of immune tolerance to self-antigens playing a part in the 
development of these conditions. In particular the IL-2 and IL-12 regulatory pathways 
have been implicated in pre-disposing to an unopposed inflammatory response 
within the liver. Main immunological themes revolve around loss of immune tolerance 
leading to T-cell mediated injury, imbalance in the regulation of immune cells and 
defective immune response to foreign antigens. For PBC and PSC there is then the 
added complexity of the consequences of cholestasis on hepato-biliary injury, 
immune regulation and liver fibrosis. 
CONCLUSIONS: Whilst specific disease causes and triggers are still lacking, 
autoimmune liver disease arises on the background of collective genetic and 
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environmental risk, leading to chronic and abnormal hepato-biliary immune 
responses.  Effective and more rational therapy will ultimately be developed when 
the multiple pathways to liver injury are better understood. 
 
 
 
Key words: Autoimmune, Cholangitis, Cirrhosis, Hepatitis, Pathophysiology. 
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Introduction 
 
The umbrella term of “autoimmune liver disease” (AILD) compromises three disease 
processes; autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary 
sclerosing cholangitis (PSC). They are an important, yet underappreciated cause of 
liver disease, with significant associated morbidity and mortality. These conditions 
affect people of all ages and persist as life-long chronic diseases.  Autoimmune 
hepatitis is a chronic immune-mediated liver disease characterised by hepatitis, the 
presence of autoantibodies and elevated IgG1. Histological features include portal 
inflammation and interface hepatitis along with lymphocytic infiltrates of both B and 
T-lymphocytes2. AIH, unlike PBC and PSC, is classically very sensitive to 
immunosuppression. Of the two main cholestatic autoimmune liver disorders, PBC is 
classically seen in women over the age of 40 and almost all are anti-mitochondrial 
antibody positive. The characteristic morphologic pattern of injury is destruction of 
small intrahepatic bile ducts [3]. Ursodeoxycholic Acid (UDCA) is the mainstay of 
management for PBC patients and benefit from treatment can be predicted by the 
biochemical response to UDCA [4]. PSC is a chronic, inflammatory cholangiopathy, 
closely associated with inflammatory bowel disease (IBD), and is very distinct from 
PBC. Histological features of PSC include lymphocytic infiltration and peri-ductal 
(onion-skin) fibrosis that progresses to stricturing and destruction of the medium-
sized intra/extra-hepatic bile ducts [5]. PSC classically affects men, and 80% will also 
be diagnosed with IBD over their lifetime [6]. PSC results in clinically significant 
cholangitis and progresses to cirrhosis and liver failure. There is a 5-10% lifetime risk 
of cholangiocarcinoma and added risks of colorectal carcinoma if IBD is present [7]. 
Currently no effective medical treatment changes disease natural history.  
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Overview of Pathogenesis 
There is likely a complex sequence of events involving genetic predisposition to 
auto-immunity (Table 1) in combination with exposure to environmental triggers 
(Table 2) that lead to the development/immunologic presentation of autoantigens, 
with a resulting aberrant (and uncontrolled) immune response leading to 
hepatic/biliary injury (Figure 1). The immune response to injury, the response of the 
hepatocyte and biliary epithelium to that injury, as well as the effects of cholestasis 
are key in determining the overall outcome, and rate of fibrosis development.  The 
risk of cancer development seems related to the degree of fibrosis in AIH and PBC, 
but in PSC cholangiocarcinoma can develop without late-stage disease suggesting 
additional pathways to malignancy [8]. 
GENETICS 
Twin studies, family studies, population studies and an inter-relationship with other 
autoimmune phenomena suggest a genetic component to risk for each disease. Until 
recently, understanding of this genetic risk has been limited to HLA haplotypes. 
Associations with risk-conferring and protective HLA haplotypes are present in all 
three diseases. Genetic observational studies have suggested that the presence of 
certain HLA alleles are associated with cholestatic liver disease, in particular HLA-
DR8 in PBC and HLA-B*08 with PSC [9]. In addition, in AIH the presence of the HLA 
haploptype DRB1*03-DRB1*04 is associated with a more aggressive disease 
phenotype [10].  How HLA associates with disease is unknown but presumed to 
reflect the strength with which relevant antigens are presented and handled by the 
immune system. Genome-wide association studies (GWAS), and related genetic 
association studies, have further increased understanding of the genetic risk 
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signature of these three diseases and autoimmunity in general. Potential functional 
implications remain to be confirmed but key findings have pointed towards the 
importance of a variety of immune and non-immune pathways e.g. IL-12/STAT4 in 
PBC, CD28-IL-2 in PSC and SH2B3 in AIH [9].   Additional pathways are of common 
relevance to the pathophysiology of autoimmunity generally (pleiotropy), and it is 
clear that a complex genetic architecture underpins some of the individual patient 
risk of developing disease. 
 
ENVIRONMENT 
Direct evidence for environmental triggers arises from drug induced AIH that has 
been described related to certain drugs, such as nitrofurantoin, and minocycline 
[11,12]. This drug-induced form of AIH gives an immunological phenotype 
indistinguishable from that of traditional AIH, including ANA/SMA antibodies and/or 
raised IgG [13]. Most cases resolve with discontinuation of the offending agent but 
this can take months or even years and, like traditional AIH, some cases can 
progress to acute liver failure or chronically to cirrhosis[11]. It is proposed that the 
mechanism of hepatotoxicity is due to drug metabolites eliciting an immune-
mediated response [14].  
Significant environmental risk factors are also associated with the development of 
PBC, include smoking, use of HRT and a history of recurrent urinary infections [15,16]. 
Some bacteria such as E.coli have been proposed to cross-react with mitochondrial 
proteins, and this may explain why recurrent urinary infections are more commonly 
seen in PBC patients than healthy controls[17].  Furthermore the role of xenobiotics in 
PBC is thought important: in PBC the lipoyl domain of the immunodominant E2 
component of pyruvate dehydrogenase (PDC-E2) can be replaced by a chemical 
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xenobiotic mimic, which experimentally can be shown to be sufficient to break self-
tolerance18.  Potential xenobiotics are speculated to be found in substances patients 
are exposed to e.g. nail varnish, hair dye, cleaning chemicals [16]. Environmental 
exposures are proposed also to be relevant to the development of PSC. Smoking 
appears to be protective [19] and given the close link between IBD and PSC, it is 
proposed that changes in the microbiome could act as an environmental trigger. 
Alternative pathways to liver damage such as ischaemia, infection and toxin related 
damage can give rise to biliary injury that mirrors PSC with each specific secondary 
insult highlighting different potential common pathways to injury [20].  
 
IMMUNOLOGY 
The main immunological themes in disease pathophysiology revolve around loss of 
immune tolerance leading to T-lymphocyte mediated cell destruction, imbalance in 
the regulation of immune cells and defective immune response to foreign antigens 
[3].Histologic studies across all three diseases with phenotypic analysis of infiltrating 
lymphocytes support this [5]. 
 
T-cells & immune tolerance: T-lymphocytes have been shown to predominate over 
other cell types in areas of interface hepatitis seen in AIH [21]. T-lymphocytes 
develop in the thymus where they interact with thymic epithelial cells (TECs) which 
express self-antigens. Thymic cortical TECs (cTECs) utilise self-antigens presented 
by MHC molecules to produce, via positive selection, T-cells which are self-tolerant. 
In comparison, thymic medullary TECs (mTECs) express different self-antigens to 
eliminate auto-reactive T cells (central tolerance) and regulate the production of 
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regulatory T-cells (Tregs). These Tregs work peripherally to dampen the immune 
response (peripheral tolerance). [22] 
Evidence for the loss of central immune tolerance in AIH comes from murine studies 
[23,24,25] and inducing non-specific T-cell activation in mice has been shown to result 
in T-cell mediated liver injury [26]. Evidence for the importance of mTECs in impaired 
central tolerance leading to AIH has also been shown experimentally [27], and is 
further corroborated by the description of a few families with AIRE deficiency: this 
gene plays a part in controlling antigen presentation in mTECs [28], and affected 
individuals suffer with autoimmune polyendocrinopathy-candidiasis-ectodermal 
dystrophy (APECED), a syndrome that includes a 20% prevalence of AIH [29]. 
 
In the development of PBC specific loss of immune tolerance to a mitochondrial 
antigen, pyruvate dehydrogenase E2 subunit (PDC-E2,) is archetypal. Such high titre 
antimitochondrial autoantibodies are directed against a highly specific epitope within 
the lipoic acid binding domain of the PDC-E2. The uniqueness of AMA epitope 
specificity alongside the conformational changes of the PDC-E2 lipoyl domain during 
physiological acyl transfer is central to disease, and as above, chemical xenobiotic 
modification of the lipoyl domain of PDC-E2 can break self-tolerance. [28] 
 
In addition, murine models of autoimmune cholangitis have indicated a role for Tregs 
and auto-reactive CD8 positive T cells in the disease process as well as a lack of 
regulatory B cells[30]. In PSC there is a clear T cell predominant infiltrate [5] but little 
knowledge to date of relevant auto-antigenic triggers. Fewer functioning Tregs can 
be demonstrated in PBC, PSC and AIH cohorts, supporting the concept of defective 
loss of immune tolerance [27,31]. 
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Cytokines & leukocyte recruitment: The recruitment of T helper 1 & 17 and 
cytotoxic CD8 T-cells into the liver via the inflamed endothelium of hepatic sinusoids 
is mechanistically important. Interactions between these cells and the hepatocyte 
lead to apoptosis of the hepatocyte. Th-17 cells produce IL-17 and IL-22 which 
promote hepatocyte regeneration. Regulatory T-cells at the site of damage act to 
control Th-1, Th-17 and cytotoxic T-cells, to limit hepatic injury. [3] 
 
All three main AILDs have been linked to abnormalities in the Th17 pathway 
[32,33,34].A higher frequency of circulating and intrahepatic Th-17 cells and their 
resulting cytokines (IL-17, IL-23) have been found in the livers of patients with AIH 
[33]. In particular, the IL-23/Th17 signalling pathway appears to be important in the 
pathogenesis of PBC but the exact mechanisms are not clear. Th17 cells secrete 
pro-inflammatory cytokines (such as IL-17 and TNFα) and promote epithelial repair 
via IL-22, when activated [3]. IL-12, IL-17 and IL-23 cytokines play an important part 
in regulating cell-mediated immunity and are implicated by genome-wide studies in 
the pathogenesis of PBC [35,36]. Patients with PBC have a preponderance of Th17 
lymphocytes and IL-12 cells infiltrating their livers [37,38]. IL-17 induces IL-6 which 
further stimulates Th-17 cells [3]. IL-12 stimulates the function of T lymphocytes and 
NK cells via activating signalling factors such as STAT4 to produce cytokines critical 
for the function of Th1 cells [39]. IL-12 is implicated in the development of other T cell 
mediated auto-immune disease, such as auto-immune myocarditis [40] and SLE 
[41].IL-12 and IL-23 are mainly produced by antigen-presenting cells and are key 
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parts of the Th-17 immune pathway. STAT 4 and Tyrosine Kinase 2 proteins are 
important for receptor signalling for the Th-17 pathway [39].  
 
The question remains whether modifying the IL-12 pathway has an effect on auto-
immune liver disease. In mouse models, deletion of the IL-12p40 subunit appears to  
lead to worsening biliary inflammation and, suggesting that  IL-12 may also have  
negative immunoregulatory functions [42]. 
 
Histological studies of patients with PSC have similarly shown a preponderance of T 
cell infiltration in the liver [43]. These T cells express IL-2 receptors, highlighting this 
pathway in disease. . IL-2 is essential for developing regulatory T cells and IL-2RA 
deficient mice develop fatal auto-immunity with peri-portal infiltrates [44]. GWAS 
studies also implicated the IL-2RA receptor as a risk locus for patients with PSC [9].  
 
Cholangiocytes, Biliary injury & Fibrosis 
In the biliary diseases PBC and PSC, the cholangiocytes are not merely passive 
victims of the immune system but are key to disease progression.  Additionally it is 
clear that cholestasis itself is potentially damaging, and that the effects of bile acid 
signalling are complex, and of relevance to immunity, metabolism and liver 
regeneration.  Powerful pathways for bile acid signalling, such as the FXR axis, have 
thus arisen as potential targets for new therapies for patients [45]. 
 
During the normal cellular life cycle, as well as in response to injury, cells, including 
cholangiocytes, are programmed to undergo apoptosis. Cholangiocytes that fail to 
complete apoptosis correctly can preserve the self-antigen on apoptotic bodies 
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(apotopes) which in turn can be recognised by auto-antibodies to create an immune 
response, a phenomenon that has been described in PBC [46].  In both PBC and 
PSC, cholangiocytes also show increased cellular senescence, wherein damaged 
cells permanently withdraw from the cell cycle but do not apoptose [47,48]. These 
cells accumulate in biliary tissue and secrete chemokines (such as CX3CL1 and 
CXCL8) and growth factors that promote immune cell recruitment and tissue repair 
[47]. These cells however cannot proliferate so damaged cells cannot be replaced, 
which may contribute to the ductopenia seen in PBC. Cholangiocytes also express 
Toll-like receptors that recognise pathogens and initiate a pro-inflammatory cascade 
to aid in tissue healing [49]. This cascade includes release of pro-inflammatory 
cytokines which recruit and activate T cells, macrophages, neutrophils and NK cells 
[3]. The presence of inflammation has been shown to cause disruptions in the tight-
junctions between cholangiocytes, thus inappropriately exposing these cells to 
potentially toxic substances, such as the constituents of bile [50]. This has been 
demonstrated in animal models of PSC [51] and can also be demonstrated in colonic 
epithelial cells [52]. Persistent exposure to antigens via the enterohepatic circulation 
could pre-dispose cholangiocytes to being pro-inflammatory, in a genetically pre-
disposed individual. These antigens may serve as “molecular mimics”, where foreign 
antigens share similar structure to self-antigens and this promotes the inflammatory 
response [3]. Lymphocytes activated in the gut can also be recruited towards the liver 
by expression of a variety of adhesion molecules, including VAP-1, which is 
expressed by the liver and recruits lymphocytes to areas of inflammation as well as 
catabolizing enteric-derived pathogens [53].  
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Bile itself is clearly not inert, containing bile acids, bilirubin, cholesterol, complex 
carbohydrates, phospholipids and proteins which can prove potentially toxic to 
cholangiocytes and hepatocytes [52]. Exposure to bile acids can result in cell 
apoptosis and necrosis [54] and cholangiocytes have mechanisms in place to protect 
them from such bile-related injury. Defects in these mechanisms can lead to injury 
and fibrosis. Once such mechanism is the binding of bile acids to cholesterol to 
prevent toxicity [55] and defects in transporter proteins that maintain this process 
(such as MDR3) have been shown to lead to biliary damage [56]. Another protective 
mechanism is the “biliary HCO3- umbrella” whereby bicarbonate is used to further 
protect cholangiocytes from bile acid damage [57] . Defects in this mechanism have 
been described in biliary disease and represent a potential target for therapy [58]. 
 
Conclusion 
 
In the absence of clear aetiologic agents for autoimmune liver diseases it is clear 
that appropriate therapy will be hampered for patients.  Nevertheless over time it has 
become more apparent that these diseases are the result of complex and dynamic 
interactions between host genetic risk and environmental exposure.  Subsequent 
immunologic and biliary driven injury results in chronic hepato-biliary inflammation 
and fibrosis.  Approaches based on these understandings will in time hopefully lead 
to better and more rational therapy for patients. 
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TABLE 1: Genetic Risk Factors for Autoimmune Liver Disease (adapted from Webb 
G, Hirschfield GM. Using GWAS to identify genetic predisposition in hepatic 
autoimmunity. J Autoimmun.2015 Sep 4.pii: S0896-8411(15)30034-2.) 
 
Diagnosis Genetic Association 
Autoimmune 
hepatitis 
HLA associations 
 
Associated with increased risk:- 
A1, B8, DQA1*05:01, DQB1*02:01, DQB1*06, 
DR4*04:04 DRB*04:05, DRB1*01, DRB1*03:01, 
DRB1*04:01, DRB1*13:01, DRB1*14, 
DRB3*01:01 
Protective:- 
DRB5*01:01, DRB1*15:01, DQB1*04, 
DQB1*03:01 
Non-HLA association 
candidate genes 
SR2B3 
Primary biliary 
cirrhosis 
HLA associations 
 
Associated with increased risk:- 
DPB1*03:01, DQA1*04:01, DQB1*03:02, 
DQB1*04:02, DQB1*04:01, DQB1*06:01, 
DRB1*04:05, DRB1*08:01, DRB1*08:03, 
DRB1*14, B*39:05 
Protective:- 
DQA1*01:02, DQA1*05:01, DQB1*03:01, 
DQB1*06:02, DQB1*06:04, DRB1*11:01, 
DRB1*11:04, DRB1*13:02, DRB1*15:01, 
B*07:02 
Non-HLA association 
candidate genes 
 
SH2B3, MMEL1, DENND18, IL1RL1, IL1RL2, 
STAT4, STAT1, CCL20, PLCL2, CD80, IL12A, , 
DGKQ, NAKB1, IL7R, IL12B, IL12RB2, OLIG3, 
ELMO1, TNFSF15, TNFSF1A,TNFSF11,  
POU2AF1, CXCR5, DDX6, LTBR, TYK2, SPIB 
Primary 
Sclerosing 
cholangitis 
HLA associations 
 
Associated with increased risk:- 
B*08:01, DRB1*03:01, DQA1*05:01, 
DQB1*02:01, DRB1*13:01, DQA1*01:03, 
DQB1*06:02, DRB1*01:01, DQA1*01:01 
Protective:- 
DQA1*02:01, DQA1*03, DQA1*05:01, 
DQB1*03:01, DQB1*03:02, DQB1*03:03, 
DRB1*04:01, DRB1*07:01, DRB1*11:01, 
DRB4*01:03, DRB4*01:03, DRB4*02:02 
Non-HLA association 
candidate genes 
SH2B3, MMEL1, TNPSFR1, BCL211, CD28, 
GPR35, MST1, IL2, IL21, BACK2, IL2RA, SIK2, 
HDAC7, FUT2, PSMG1 
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TABLE 2: Environmental Risk Factors associated with development of autoimmune 
liver injury  
 Associations with 
disease 
Autoimmune hepatitis Nitrofurantoin 
Minocycline 
Hepatitis A infection 
 
Primary biliary cirrhosis Smoking 
HRT 
Frequent urinary 
infections 
Nail varnish 
Hair dye 
Cholestasis of 
pregnancy 
Industrial waste sites 
Paracetamol use 
 
Primary Sclerosing 
cholangitis 
Inflammatory bowel 
disease 
Smoking (protective) 
Coffee 
Hormonal 
contraception 
Diet 
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FIGURE 1: Overview of the pathogenesis of autoimmune liver disease.  
 
There is likely a complex sequence of events that occur in the development of AILD. 
A genetic predisposition to auto-immunity in combination with exposure to 
environmental triggers leads to the development of CD4 T helper cells which are 
activated to recognise autoantigens. This can lead to a variety of immune responses, 
all of which can lead to tissue damage; the Th1 response involving IL-2 in the 
differentiation of CD8 cytotoxic T cells and macrophages; the Th17 response 
involving IL-17 and IL-23; the Th2 response involving IL-4, IL-10 and IL-13 as well as 
differentiation of B cells into plasma cells resulting in immunoglobulin production as 
well as activation of monocytes and Natural Killer (NK) cells; Defective cell 
homeostasis results in increased cell senescence and defective apoptosis. 
Decreased numbers of circulating Tregs affects all of these pathways. A combination 
of these immune responses leads to tissue injury, although it is not certain exactly 
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what factors are involved in the development of biliary or hepatic-predominant 
disease. 
 
